Clinical Trial Search

Primary: Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control…

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001

Primary: Annual Asthma Exacerbation Rate (AERR) — 0.42; 1.63 Events per year — p=<0.001

Primary: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants — 0.57; 0.65; 0.37; 0.34 AER events/person-year — p=0.781

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800

Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI

Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049

Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute

Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52

Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.043; 0.232; 0.229; 0.221 Liters — p=<0.001

Primary: Rate of Severe Asthma Exacerbations During 6 Months — 0.31; 0.31; 0.26; 0.20 Exacerbations per 6 month — p=0.119

Primary: Morning Peak Expiratory Flow (mPEF) — 346.42; 362.54; 352.87; 329.75 L/min

Primary: Annualised Asthma Exacerbation Rate (AAER) up to Week 52 — 0.80; 0.95; 0.87; 0.77 Events/year — p=0.4656

Primary: Annualised Asthma Exacerbation Rate (AAER) up to Week 52 — 0.56; 0.54; 0.60 Events/year — p=0.5859

Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — 0.137; 0.239; 0.266; 0.341 Liters — p=0.095

Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale

Primary: The Medication Treatment Step Assigned — 4.03; 4.05 score on a scale

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059

Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.065; 0.142; 0.173; 0.228 Liters — p=<0.001

Primary: Asthma Control Questionnaire (ACQ) Score at Baseline — 2.24; 2.15; 2.19 units on a scale

Primary: Rate of Asthma Exacerbations Over the 48 Week Treatment Period — 0.88; 0.66 exacerbation/patient-week

Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period — 27.03; 18.18 L/min

Primary: Percentage of Patients With Suspected Adverse Drug Reactions (ADRs) — 5.59 Percentage of participants

Primary: Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL — 0.49; 1.88 events/patient-year…

Primary: Time to Treatment Failure (Measured in Days) — 196.9; 225.2; 182.3 days

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL — 0.73; 0.65; 1.33 events/year — p=<0.001

Primary: Asthma Control — 1.857; 1.592; 1.792; 1.578 units on a scale — p=0.046

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2